MONOCYTE/HER2 VACCINE IN BREAST AND OVARIAN CANCER PATIENTS

我们将研究HER2阳性的乳腺癌和卵巢癌HLA-A2+患者的细胞和体液免疫反应的因素。患者将接受皮内接种自体单核细胞，这些单核细胞通过体外培养表达her2衍生肽。接种疫苗后，将对患者进行外周血、接种部位、生理盐水对照接种部位和转移性肿瘤部位（如有可能）取样。疫苗接种诱导的细胞介导的抗肿瘤活性将被研究，从这些部位分离的细胞将在体外检测在体外抗HER2抗体不存在（特异性细胞毒性）或存在（抗体依赖性细胞毒性）的情况下裂解HER2阳性细胞系的能力。通过测定血清循环内源性抗her2抗体的数量，研究接种前后的体液抗肿瘤反应。

We will study elements of the cellular and humoral immune responses in HLA-A2+ patients with breast and ovarian cancer whose tumors are HER2 positive. Patients will receive intradermal vaccination with autologous monocytes which have been made to express HER2-derived peptide by in vitro incubation with the peptide. Following vaccination they will have sampling of peripheral blood, vaccination site, saline control vaccination site, and metastatic tumor site (if accessible). Cell-mediated anti-tumor activity induced by vaccination will be studied as cells isolated from these sites are assayed in vitro for ability to lyse HER2 positive cell lines in the absence (specific cytotoxicity) or presence (antibody-dependent cytotoxicity) of in vitro anti-HER2 antibody. Humoral antitumor response before and after vaccination will be studied by assaying serum for the amount of circulating endogenous anti-HER2 antibody.